|
Malignant neoplasm of stomach
|
0.320 |
Biomarker
|
disease |
BEFREE |
We further tried to investigate the effects of UBR5 on gastric cancer cell growth in vitro and in vivo.
|
27590582 |
2016 |
|
Stomach Carcinoma
|
0.320 |
Biomarker
|
disease |
BEFREE |
We further tried to investigate the effects of UBR5 on gastric cancer cell growth in vitro and in vivo.
|
27590582 |
2016 |
|
Malignant neoplasm of stomach
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Further analyses to examine the joint effect of MBL2 and IL-1B polymorphisms, previously shown to predispose to stomach cancer, indicated that the combination of at-risk IL-1B genotypes (CT or TT at location -511) and HYD MBL2 haplotype was associated with a 3.5-fold risk (OR = 3.5, 95% CI 1.6-7.6; p = 0.001).
|
16721783 |
2006 |
|
Stomach Carcinoma
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Further analyses to examine the joint effect of MBL2 and IL-1B polymorphisms, previously shown to predispose to stomach cancer, indicated that the combination of at-risk IL-1B genotypes (CT or TT at location -511) and HYD MBL2 haplotype was associated with a 3.5-fold risk (OR = 3.5, 95% CI 1.6-7.6; p = 0.001).
|
16721783 |
2006 |
|
Malignant neoplasm of stomach
|
0.320 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Stomach Carcinoma
|
0.320 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.
|
23407552 |
2013 |
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.310 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Stomach Neoplasms
|
0.300 |
CausalMutation
|
group |
CGI |
|
|
|
|
Benign neoplasm of stomach
|
0.300 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Carcinoma in situ of stomach
|
0.300 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Neoplasm of uncertain or unknown behavior of stomach
|
0.300 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Adenocarcinoma of large intestine
|
0.300 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
UBR5 overexpression was significantly associated with tumor size, histological and tumor differentiation.
|
30775814 |
2019 |
|
Finding of Mean Corpuscular Hemoglobin
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HYD-PEP06 is a novel RGD-modified Endostar mimetic peptide with 30 amino acids that is intended to suppress the formation of neoplasm vessels.
|
29935477 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Results showed circ-UBR5 expression was significantly downregulated in NSCLC tissues (p < 0.001) and was correlated with tumor differentiation (p = 0.00126), suggesting circ-UBR5 might serve as an index of NSCLC differentiation.
|
29944885 |
2018 |
|
mathematical ability
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals.
|
30038396 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings unveil UBR5 as a novel and critical regulator of tumor growth, metastasis, and immune response and highlight the potential for UBR5 as an effective therapeutic target for the treatment of highly aggressive breast and ovarian cancers that fail conventional therapy.<i></i>.
|
28330927 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An <i>in vivo</i> animal model further confirmed that UBR5 knockdown reduced the growth of CRC tumors.
|
29296225 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, we found that UBR5 directly binds to the tumor suppressor esophageal cancer-related gene 4 (ECRG4) and increased its ubiquitination to reduce the protein stability of ECRG4.
|
28856538 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The E3 ligase UBR5 regulates gastric cancer cell growth by destabilizing the tumor suppressor GKN1.
|
27590582 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo, mouse intraperitoneal ES-2 and A2780ip2 xenograft experiments showed that mice treated with EDD siRNA by nanoliposomal delivery [1,2-dioleoyl-sn-glycero-3-phophatidylcholine (DOPC)] and cisplatin had significantly less tumor burden than those treated with control siRNA/DOPC alone (ES-2, 77.9% reduction, P = 0.004; A2780ip2, 75.9% reduction, P = 0.042) or control siRNA/DOPC with cisplatin in ES-2 (64.4% reduction, P = 0.035), with a trend in A2780ip2 (60.3% reduction, P = 0.168).
|
24379240 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, the B55α-EDD-p53 pathway is essential for cancer cell survival and tumor growth under low glutamine conditions in vitro and in vivo.
|
23499005 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Constitutive expression of UBR5-ZNF423 in NIH3T3 fibroblasts significantly enhanced its anchorage-independent growth in soft agar and induced tumour formation in a nude mouse model.
|
23878065 |
2013 |